
SLP — Simulations Plus Inc
NASDAQ · Healthcare · Health Information Services
$18.42
+$0.02 (+0.11%)
Simulations Plus Inc (SLP) is a health information services company listed on NASDAQ. It is led by Shawn M. O'Connor, based in 800 Park Offices Drive, Research Triangle Park, NC, United States, 27709, with about 212 employees. Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
Latest reported SLP revenue for 2025-08-31 was $79.2M. Net income was -$64.7M. Revenue was up 288.8% from 2025-05-31 to 2025-08-31. SLP currently screens at market cap $368.8M.
Use this SLP page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SLP quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SLP SEC filings page. Lician reads the product cache first so this HTML stays unique to Simulations Plus Inc even when a live quote feed is slow.
About Simulations Plus Inc
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
SLP Key Statistics
Market Cap
$368.75M
Volume
169,861
Previous Close
$18.40
Day Range
$18.38 – $18.41
P/B Ratio
2.76
EPS
-$3.22
Revenue
$79.18M
Net Income
-$64.72M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+13.1%
Profit Margin
-81.7%
Employees
212
SLP Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $79.18M | $70.01M | $59.58M | $53.91M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$64.72M | $9.95M | $9.96M | $12.48M |
| EPS (Diluted) | -$3.22 | $0.49 | $0.49 | $0.60 |
Total Assets
$131.94M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$30.85M
Operating Cash Flow
$18.13M
Free Cash Flow
$0.00
Simulations Plus Inc Company Information
- Chief Executive Officer
- Shawn M. O'Connor
- Headquarters
- 800 Park Offices Drive, Research Triangle Park, NC, United States, 27709
- Website
- www.simulations-plus.com
- Phone
- 661 723 7723
- IPO / Founded
- 1997-06-18
- Sector
- Healthcare
- Industry
- Health Information Services